BioNTech SE (NASDAQ:BNTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of BioNTech SE (NASDAQ:BNTX) have been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $109.09.

A number of research analysts have weighed in on BNTX shares. Evercore ISI started coverage on shares of BioNTech in a research note on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price objective on the stock. BMO Capital Markets dropped their price target on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and set a $113.00 price objective on shares of BioNTech in a report on Monday, August 19th. HSBC raised BioNTech from a “hold” rating to a “buy” rating in a research note on Friday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft upgraded BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price target for the company in a report on Wednesday, August 7th.

Institutional Investors Weigh In On BioNTech

Hedge funds have recently made changes to their positions in the business. Granite Bay Wealth Management LLC purchased a new stake in BioNTech during the second quarter worth about $1,483,000. Scientech Research LLC bought a new position in shares of BioNTech during the 2nd quarter valued at approximately $1,127,000. Deerfield Management Company L.P. Series C increased its stake in shares of BioNTech by 4.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after purchasing an additional 24,426 shares during the last quarter. Employees Retirement System of Texas raised its holdings in shares of BioNTech by 15.7% in the 2nd quarter. Employees Retirement System of Texas now owns 30,388 shares of the company’s stock worth $2,442,000 after purchasing an additional 4,115 shares during the period. Finally, Caxton Associates LP purchased a new position in BioNTech in the second quarter valued at approximately $682,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Stock Up 1.1 %

BNTX stock opened at $88.19 on Monday. The stock’s 50 day simple moving average is $83.88 and its 200 day simple moving average is $89.49. The company has a market cap of $20.97 billion, a P/E ratio of 176.38 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $125.83.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The firm had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. During the same quarter in the prior year, the firm earned ($0.86) EPS. The company’s revenue was down 23.3% compared to the same quarter last year. On average, research analysts expect that BioNTech will post -2.04 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.